SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Rallybio Corporation (Nasdaq – RLYB)
BALA CYNWYD – June 2, 2026/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Rallybio Corporation (“Rallybio” or the “Company”) (Nasdaq – RLYB) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Avenso Therapeutics, Inc. (“Avenso”) Following closing, pre-Transaction Rallybio holders are expected to own approximately 2.8% of the combined company. Pre-closing Rallybio stockholders will also receive contingent value rights (“CVRs”) entitling them to the net cash proceeds received by the combined company from the previously announced sale of interests in Rallybio’s former REV102 program and potential disposition of Rallybio’s other legacy assets. Upon completion of the Merger, the combined company is expected to operate under the name Avenzo Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol “AVZO.”
The investigation concerns whether the Rallybio Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders.
If you own shares of Rallybio stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.